It activated the necrosome complex and overcame the resistance of Ph+ CML to BCR-ABL TKI and RCC cells to sunitinib.361,367 In addition, shikonin downregulated cell cycle-activating proteins and inhibited the proliferation of drug-resistant cells through cycle arrest. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.